Other Companies

A | C | E | G | I | L | M | N | P

A

AKESOgen, Inc.

Current Status: AKESOgen was aquired by Tempus in 2019. Tempus no longer has a license to Emory technology.

Company Profile: AKESOgen was aquired by Tempus in 2019. AKESOgen was a biomarker, genomics, and pharmacogenomics contract research organization that services the academic, pharmaceutical, biotechnology and agricultural sectors. They perform biomarker profiling and genomics services utilizing different types of markers (e.g., DNA, RNA, methylation) for the R&D market. They also establish and validate biomarkers in the clinical trials arena and provide expertise in biobanking.

Affiliation with Emory: Mark Bouzyk, PhD (human genetics) was a founder.

C

Centripital, Inc.

Address: 812 Sherwood Rd. Atlanta, GA 30322

Founder: Jason Stein

Current Status: Products on the market

Company Profile: Centripital is a not-for-profit whose mission is to train hospital professionals so that they can work together in high-functioning and patient-centered teams. They have translated a decade of local, national and international experience in integrating science into a transferable approach for standardizing inter-professional hospital teamwork and effective unit-design. Centripital's care model has been associated with improvements in hospital mortality, length of stay, and patient satisfaction. Centripital licenses out its implementation know-how.

Affiliation with Emory: Jason Stein, MD (hospital medicine) is a founder.

Clearside Biomedical, Inc.

Address: 1220 Old Alpharetta Road, Suite 300, Alpharetta, GA 30005
Clearside Biomedical website

President & CEO: Daniel White

Current Status: In clinical trails

Company Profile: Clearside Biomedical is a clinical stage ophthalmic therapeutics company improving drug performance through tissue targeted microinjection into distinct compartments of the eye to treat sight threatening disease. The company’s lead product is CLS1001, triamcinolone acetonide in a suprachoroidal microinjection device.

Affiliation with Emory: Henry Edelhauser, PhD (opthamology) is an inventor.

CrystalPlex Corp.

Current Status: CyrstalPlex no longer has a license to Emory technology.

Company Profile: CrystalPlex developed and commercialized semiconductor nanocrystals, also known as quantum dots, for optoelectronics, security and life sciences. The company's TriLite nanocrystals were manufactured using alloy gradient technology, and were brighter and more stable than standard nanocrystals. They are used as down-converting phosphors and direct emitters in display and lighting. For security applications, TriLite nanocrystals are used as fluorescent taggants where a distinct photonic signature or marking is necessary.

Affiliation to Emory: Emory alumnus Lianhua Qu, PhD is a scientific founder.

E

Easy Mask, Inc.

Address: 10635 Garda Dr, Trinity, FL 34655
Easy Mask Website

CEO: Todd Doering

Current Status: Performing market research and customer discovery

Company Profile: Easy Mask’s is developing technology to modify glasses, safety glasses and face shields to eliminate fog formation. It is a simple but highly effective design that can be integrated into existing mask designs and can be produced at a low cost to help combat the non-compliant use of safety eyewear.

Affiliation to Emory: Jill Morgan, RN (Emory University Hospital) is an inventor.

G

GT Plus

Current Status: GT Plus is no longer in business.

Company Profile: GT Plus focused on antimicrobial coatings to prevent the growth of mold, mildew, bacteria, and fungus on various surfaces.

Affiliation with Emory:  Lanny Liebeskind, PhD (chemistry) is an inventor.

I

Incintas Therapeutics, Inc.

Address: 12 Moccasin Drive, Atglen, PA 19310

President & CEO: Jesse Pizolato

Current Status: In preclinical development

Company Profile: Incintas Therapeutics is focusing on failed embryonic implantation in IV, which is the inability of an embryo to attach to the uterine wall. The technology is a targetd, intrauterine means of hormonally preparing the uterus for implantation in IVF cycles by enhancing and completing fluid transport of the embryo to the uterine surface. The technology also has a possibility of providing a therapeutic for uterine pathologies such as polycystic ovarian syndrome, endometriosis, and ectopic pregnancy.

Affiliation with Emory: Emory alumnus Jesse Pizolato is the scientific founder.

L

LAAMScience, Inc.

Current Status: LAAMScience is no longer in business.

Company Profile: LAAMScience was a nanotechnology company that has developed medical and consumer products incorporating a proprietary anti-microbial coating. SERQET™ was used in respirator masks, surgical masks, cleaning wipes, and dishwashing towels. The nanocoating technology killed bacteria and viruses when it was exposed to visible light. This coating can be applied to almost any fabric.

Affiliation with Emory: Gordon Churchward, PhD (microbiology and immunology) is an inventor.

M

Metaclipse Therapeutics Corp.

Address: 3175 Presidential Drive, Atlanta GA 30340
Metaclipse Therapeutics Website

CEO: Michael Coleman

Current Status: In preclinical stage

Company Profile: Metaclipse Therapeutics is an early-stage biotechnology company developing novel cancer therapies that are tailored to each patient and their specific tumor. The company's first 'personalized' cancer therapy is for treating metastatic breast cancer, a highly differentiated disease of mainly women. The products is designed to activate the body's immune system to mount a broad and robust attack against metastatic cancer cells. These products are well-defined pharmaceutical 'biological' products and consist of micron-size 'vesicles' manufactured from tumor cell membranes taken from the patient that the company augments using a proprietary 'protein transfer' method with clinically proven immunostimulatory proteins. After dermal administration, these modified vesicles present to the immune system both these immunostimulatory proteins and an array of patient-specific tumor-membrane antigens. This creates a tumor-specific cellular and humoral immunity that Metaclipse anticipates can destroy and/or suppress the growth of metastatic cancer cells originating from the patient's primary tumor.

Affiliation with Emory: Periasamy Selvaraj, PhD (pathology), Sampath Ramachandiran (hematology), Christopher Pack (pathology) and Ramireddy Bommireddy (pathology) are inventors.

N

NatGlycan, LLC

Address: 2342 Oakshire Ct, Decatur, GA 30033
NatGlycan website

President & CEO: David F. Smith

Current Status: Products on the market

Company Profile: NatGlycan has developed a proprietary strategy for the processing of large quantities of natural biological sources including mammalian tissue and organs into glycans. The company has a proprietary glycan extraction technique for production.

Affiliation with Emory: David Smith, PhD (biochemistry) and Xuezheng Song, PhD (biochemistry) are scientific co-founders.

NBS Technology, LLC

Current Status: NBS Technology is no longer in business.

Company Profile: NBS Technology was focused on antimicrobial coatings to prevent the growth of mold, mildew, bacteria, and fungus on various surfaces.

Affiliation with Emory: Lanny Liebeskind, PhD (chemistry) is an inventor.

P

Primatope Therapeutics, Inc.

Address: 508 Dudley Rd, Suite 400, Newton, MA 02459

President & CEO: Mark A. Tepper

Current Status: In preclinical development

Company Profile: Primatope Therapeutics is developing therapeutic antibodies that can be used to control inflammation and transplant rejection. A new monoclonal antibody against the B cell antigen CD40 that, upon binding, is capable of blocking the signaling interaction of CD40 with its ligand, CD154, on T cells. By blocking B cell activation and inducing immunosuppression, this antibody may reduce the likelihood of, or increase the duration prior to, transplant rejection or be used to treat autoimmune disorder.

Affiliation with Emory: Christian Larsen, MD, PhD (surgery) is an inventor.